Full Press Release Details
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Feb. 6, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, President & Chief Executive Officer, will provide a corporate overview at the BIO CEO & Investor Conference, being held February 12-13 at the New York Marriott Marquis Hotel in New York City.
BIO CEO & Investor Conference Presentation Details
| Date: | Monday, February 12 |
| Time: | 2:00pm Eastern Time |
| Location: | New York Marriott Marquis, Wilder Room |
| Webcast: | https://goo.gl/Dj4Dvc |
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U.S., a clinically meaningful benefit was demonstrated by a higher response to NurOwn® compared with placebo. For more information, visit the company's website at www.brainstorm-cell.com.
Chief Business Officer
BrainStorm Cell Therapeutics Inc.
LifeSci Advisors LLC
Matt Middleman, M.D.
LifeSci Public Relations, LLC
SOURCE BrainStorm Cell Therapeutics Inc.
Related Links
21 %
more press release views with